Pacira BioSciences received FDA approval on its supplemental drug application for expanding the Exparel label in order to include adult administration as an adductor cannula block as well as sciatic nerve blocking in the popliteal fosse.
According to a press release by the company, the FDA approval came after Exparel, (bupivacaine injectable liposome suspension), showed successful safety and efficacy data vs. bupivacaine HCI.
“In line with our corporate mission to provide a non-opioid to as many patients as possible, this new indication provides additional flexibility
